Evidence map›Paper›PMID 35074600›Full record

ArticleThe journal of allergy and clinical immunology. In practice2022

Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.

Julien Rossignol, Amani Ouedrani, Cristina Bulai Livideanu, Stéphane Barete, Louis Terriou, David Launay, Richard Lemal, Celine Greco, Laurent Frenzel, Cecile Meni and 45 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

55 authors at 20 institutions in 1 country.

Julien RossignolFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France; Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France.
Amani OuedraniParis University, Necker-Enfants Malades Institute, CNRS UMR 8253 and INSERM UMR1151, Necker-Enfants Malades University Hospital, Paris, France; Laboratory of Immunoregulation and Immunopathology, Necker-Enfants Malades University Hospital, APHP, Paris, France.
Cristina Bulai LivideanuFrench Reference Center for Mastocytosis (CEREMAST), Department of Dermatology, Hôpital Larrey, Toulouse University Hospital, Toulouse, France.
Stéphane BareteFrench Reference Center for Mastocytosis (CEREMAST), Department of Dermatology, Pitié-Salpêtrière University Hospital, APHP, Paris, France.
Louis TerriouUniversity Lille, INSERM, CHU Lille, Department of Internal Medicine and Clinical Immunology, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
David LaunayUniversity Lille, INSERM, CHU Lille, Department of Internal Medicine and Clinical Immunology, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Richard LemalAdult Clinical Hematology, Clermont-Ferrand University Hospital, INSERM CIC501, EA 7453-Université Clermont Auvergne, Clermont-Ferrand, France.
Celine GrecoFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France; Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France.
Laurent FrenzelFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France; Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France.
Cecile MeniFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France.
Christine Bodemere-SkandalisFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France; Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France.
Laura PolivkaFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France; Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France.
Anne-Florence CollangeFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France; Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France.
Hassiba HachichiFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France.
Sonia BouzourineFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France.
Djazira Nait MessaoudFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France.
Mathilde NegrettoFrench Reference Center for Mastocytosis (CEREMAST), Department of Dermatology, Hôpital Larrey, Toulouse University Hospital, Toulouse, France.
Laurence VendrameParis University, Necker-Enfants Malades Institute, CNRS UMR 8253 and INSERM UMR1151, Necker-Enfants Malades University Hospital, Paris, France.
Marguerite JambouParis University, Necker-Enfants Malades Institute, CNRS UMR 8253 and INSERM UMR1151, Necker-Enfants Malades University Hospital, Paris, France.
Marie GousseffDepartment of Internal Medicine, Bretagne Atlantique Hospital, Vannes, France.
Stéphane DuruptDepartment of Internal Medicine, Adult Cystic Fibrosis Care Center, Hospices Civils de Lyon, Lyon, France.
Jean-Christophe LegaDepartment of Internal Medicine, Adult Cystic Fibrosis Care Center, Hospices Civils de Lyon, Lyon, France.
Jean-Marc DurandDepartment of Internal Medicine, Aix-Marseille University, Timone University Hospital, Marseille, France.
Caroline GaudyDepartment of Internal Medicine, Aix-Marseille University, Timone University Hospital, Marseille, France.
Gandhi DamajHaematology Institute, Normandy University School of Medicine, Caen, France.
Marie-Pierre GourinLaboratory of Hematology, Dupuytren University Hospital, Limoges, France.
Mohamed HamidouDepartment of Internal Medicine, Hôtel-Dieu University Hospital, Nantes, France.
Laurence BouilletClinical Immunology/Internal Medicine Department, National Reference Center for Angioedema, Grenoble University Hospital, Grenoble, France.
Edwige Le MouelDepartment of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France.
Alexandre MariaDepartment of Internal Medicine, Montpellier University Hospital, Montpellier, France.
Patricia ZunicDepartment of Haematology, Sud Réunion University Hospital, Saint Pierre, La Réunion, France.
Quentin CabreraDepartment of Haematology, Sud Réunion University Hospital, Saint Pierre, La Réunion, France.
Denis VincentDepartment of Pneumology and Internal Medicine, Caremeau University Hospital, Nimes, France.
Christian LavigneDepartment of Internal Medicine, Angers University Hospital, Angers, France.
Etienne RiviereDepartment of Internal Medicine, Bordeaux University Hospital, Haut-Lévêque Hospital, Pessac, France.
Clement GourguechonDepartment of Hematology, Amiens University Hospital, Amiens, France.
Marie CourbebaisseParis University, Necker-Enfants Malades Institute, CNRS UMR 8253 and INSERM UMR1151, Necker-Enfants Malades University Hospital, Paris, France; Department of Physiology-Functional Renal Explorations, Hôpital Européen Georges Pompidou University Hospital, Paris, France.
David LebeauxService de Microbiologie, Unité Mobile d'Infectiologie, AP-HP, Hôpital Européen Georges Pompidou, Paris, France; Université de Paris, Paris, France.
Béatrice ParfaitCentre de Ressources Biologiques, Hôpital Cochin, Paris, France; Paris University, Institut Cochin INSERM UMR1016, Paris, France.
Gérard FriedlanderParis University, Necker-Enfants Malades Institute, CNRS UMR 8253 and INSERM UMR1151, Necker-Enfants Malades University Hospital, Paris, France.
Anne BrignierTherapeutic Apheresis Unit, Saint-Louis University Hospital, APHP, Paris, France.
Ludovic LhermitteLaboratory of Onco-Hematology, Necker-Enfants Malades University Hospital, APHP, Paris, France.
Thierry Jo MolinaParis University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France; Pathology Department, Necker-Enfants Malades University Hospital, APHP, Paris, France.
Julie BruneauParis University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France; Pathology Department, Necker-Enfants Malades University Hospital, APHP, Paris, France.
Julie AgopianCRCM, [Signaling, Hematopoiesis and Mechanism of Oncogenesis, CEREMAST, AFIRMM], INSERM U1068, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Aix-Marseille Univ, UM105, Marseille, France; CNRS, UMR7258, Marseille, France.
Patrice DubreuilCRCM, [Signaling, Hematopoiesis and Mechanism of Oncogenesis, CEREMAST, AFIRMM], INSERM U1068, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Aix-Marseille Univ, UM105, Marseille, France; CNRS, UMR7258, Marseille, France.
Dana RantaDepartment of Haematology, Nancy University Hospital, Nancy, France.
Alexandre ManiaAdult Clinical Hematology, Clermont-Ferrand University Hospital, INSERM CIC501, EA 7453-Université Clermont Auvergne, Clermont-Ferrand, France.
Michel ArockLaboratory of Haematology, Pitié-Salpêtrière University Hospital, Paris, France.
Isabelle StaropoliVirus & Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR3569, Paris, France.
Olivier TournilhacAdult Clinical Hematology, Clermont-Ferrand University Hospital, INSERM CIC501, EA 7453-Université Clermont Auvergne, Clermont-Ferrand, France.
Olivier LortholaryFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France; Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France.
Olivier SchwartzVirus & Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR3569, Paris, France.
Lucienne ChatenoudParis University, Necker-Enfants Malades Institute, CNRS UMR 8253 and INSERM UMR1151, Necker-Enfants Malades University Hospital, Paris, France; Laboratory of Immunoregulation and Immunopathology, Necker-Enfants Malades University Hospital, APHP, Paris, France.
Olivier HermineFrench Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France; Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France. Electronic address: ohermine@gmail.com.
Centre National de la Recherche Scientifique · FRInserm · FRHôpital Necker-Enfants Malades · FRAssistance Publique – Hôpitaux de Paris · FRAix-Marseille Université · FRCentre Hospitalier Universitaire de La Réunion · FRHôpital Larrey · FRHospices Civils de Lyon · FRCentre hospitalier Bretagne Atlantique · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire Amiens-Picardie · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Nîmes · FRCentre Hospitalier Universitaire de Rennes · FRHôpital Cardiologique du Haut-Lévêque · FRHôpital Dupuytren · FRInstitut Necker Enfants Malades · FRSorbonne Université · FRUniversité d'Angers · FRUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMast cells are key players in innate immunity and the T

objectiveTo study a comprehensive range of outcomes in patients with cMCAD with PCR- or serologically confirmed coronavirus disease 2019 and to characterize the specific anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response in this setting.

methodsClinical follow-up and outcome data were collected prospectively over a 12-month period by members of the French Centre de Référence des Mastocytoses rare disease network. Anti-SARS-CoV-2-specific T-cell activity was measured with an ELISA, and humoral responses were evaluated by assaying circulating levels of specific IgG, IgA, and neutralizing antibodies.

resultsOverall, 32 patients with cMCAD were evaluated. None required noninvasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2-specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2-specific, IFN-γ-producing T cells and high titers of neutralizing antispike IgGs. The patients frequently showed spontaneous T-cell IFN-γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden).

conclusionsPatients with cMCADs might not be at risk of severe coronavirus disease 2019, perhaps due to their spontaneous production of IFN-γ.

Indexed as

COVID-19MastocytosisAntibodies, ViralHumansImmunityMast CellsSARS-CoV-2Antibodies, ViralB cellsClonal mast cell activation syndromeCOVID-19Mast cell activation disordersMast cellsMastocytosisSARS-CoV-2T cells

Identifiers

PMID35074600
PMCPMC8780123
OpenAlexW4205879630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.